JP2009518024A - Egfrおよび/またはvegfに対して結合特異性を有するリガンドおよびその使用法 - Google Patents

Egfrおよび/またはvegfに対して結合特異性を有するリガンドおよびその使用法 Download PDF

Info

Publication number
JP2009518024A
JP2009518024A JP2008543892A JP2008543892A JP2009518024A JP 2009518024 A JP2009518024 A JP 2009518024A JP 2008543892 A JP2008543892 A JP 2008543892A JP 2008543892 A JP2008543892 A JP 2008543892A JP 2009518024 A JP2009518024 A JP 2009518024A
Authority
JP
Japan
Prior art keywords
seq
dom16
egfr
ligand
tar15
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008543892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518024A5 (enExample
Inventor
イグナトヴィッチ,オルガ
ホームズ,スティーブ
ベックマン,ローランド
リュー,ハイクン
ウィルト,ルドルフ,エム.ティー. デ
ジェスパース,ローレント,エス.
スチュワード,マイケル
セップ,アルミン
プペッカ,マルゴーザタ
Original Assignee
ドマンティス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドマンティス リミテッド filed Critical ドマンティス リミテッド
Publication of JP2009518024A publication Critical patent/JP2009518024A/ja
Publication of JP2009518024A5 publication Critical patent/JP2009518024A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008543892A 2005-12-06 2006-12-05 Egfrおよび/またはvegfに対して結合特異性を有するリガンドおよびその使用法 Pending JP2009518024A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74299205P 2005-12-06 2005-12-06
US75835506P 2006-01-11 2006-01-11
PCT/GB2006/004559 WO2007066106A1 (en) 2005-12-06 2006-12-05 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor

Publications (2)

Publication Number Publication Date
JP2009518024A true JP2009518024A (ja) 2009-05-07
JP2009518024A5 JP2009518024A5 (enExample) 2009-12-24

Family

ID=37820653

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008543892A Pending JP2009518024A (ja) 2005-12-06 2006-12-05 Egfrおよび/またはvegfに対して結合特異性を有するリガンドおよびその使用法

Country Status (13)

Country Link
US (2) US20100056439A1 (enExample)
EP (1) EP1966242A1 (enExample)
JP (1) JP2009518024A (enExample)
KR (1) KR20080077261A (enExample)
AU (1) AU2006323412A1 (enExample)
BR (1) BRPI0619463A2 (enExample)
CA (1) CA2632417A1 (enExample)
CR (1) CR10024A (enExample)
EA (1) EA013878B1 (enExample)
MA (1) MA30021B1 (enExample)
NO (1) NO20082386L (enExample)
TW (1) TW200804425A (enExample)
WO (1) WO2007066106A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527877A (ja) * 2009-05-28 2012-11-12 グラクソ グループ リミテッド 抗原結合性タンパク質
JP2012532620A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
JP2014501725A (ja) * 2010-11-24 2014-01-23 グラクソ グループ リミテッド Hgfを標的とする多特異的抗原結合タンパク質
JP2017195874A (ja) * 2016-04-26 2017-11-02 コリア プライム ファーム カンパニー リミテッドKorea Prime Pharm Co., Ltd. 血管内皮成長因子融合タンパク質

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
UY31504A1 (es) * 2007-11-30 2009-07-17 Construcciones de union de antigenos
CA2707986A1 (en) * 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
NZ586701A (en) 2008-01-03 2013-07-26 Scripps Research Inst Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
CA2718480A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽,以及包含其的化合物、构建体和多肽
WO2010033249A2 (en) * 2008-09-22 2010-03-25 Massachusetts Institute Of Technology Compositions of and methods using ligand dimers
WO2010046337A2 (en) * 2008-10-21 2010-04-29 Domantis Limited Ligands that have binding specificity for dc-sign
CN102224169A (zh) * 2008-11-26 2011-10-19 葛兰素集团有限公司 多肽、抗体可变结构域和拮抗剂
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
EA022925B1 (ru) * 2009-02-19 2016-03-31 Глаксо Груп Лимитед Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
RU2011138951A (ru) 2009-02-23 2013-03-27 Сайтомкс Терапьютикс, Инк. Пропротеины и способы их применения
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EA201390116A1 (ru) * 2010-08-20 2013-09-30 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Улучшенные связывающие варианты против сывороточного альбумина
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US20140255471A1 (en) 2013-03-11 2014-09-11 Wake Forest University Health Sciences Method of treating brain tumors
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
CN105814082A (zh) * 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス,インコーポレイティド 非免疫原性単一ドメイン抗体
CA2974720A1 (en) * 2015-02-06 2016-08-11 University Of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
PL3322734T3 (pl) 2015-07-16 2021-05-04 Inhibrx, Inc. Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5
EP3768722A4 (en) * 2018-03-19 2021-12-29 Wuxi Biologics Ireland Limited. Novel anti-egfr antibody polypeptide
CN113874396B (zh) * 2019-03-29 2024-01-05 株式会社绿十字 包含抗间皮素抗体、抗cd3抗体或抗egfr抗体的融合蛋白、包含所述融合蛋白的双特异性或三特异性抗体,及其用途
US12043652B2 (en) 2020-08-28 2024-07-23 Trustees Of Boston University Engineered extracellular receptor constructs and uses thereof
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510922A (ja) * 1994-03-17 1996-11-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗EGFR一本鎖Fvおよび抗EGFR抗体
JP2001509817A (ja) * 1997-04-07 2001-07-24 ジェネンテク・インコーポレイテッド 抗vegf抗体
US20020058033A1 (en) * 2000-10-13 2002-05-16 Raisch Kevin Paul Human anti-epidermal growth factor receptor single-chain antibodies
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2004081026A2 (en) * 2003-06-30 2004-09-23 Domantis Limited Polypeptides
WO2005012359A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Anti-vegf antibodies
WO2005044858A1 (en) * 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT957929E (pt) * 1996-10-25 2006-06-30 Gilead Sciences Inc Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510922A (ja) * 1994-03-17 1996-11-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗EGFR一本鎖Fvおよび抗EGFR抗体
JP2001509817A (ja) * 1997-04-07 2001-07-24 ジェネンテク・インコーポレイテッド 抗vegf抗体
US20020058033A1 (en) * 2000-10-13 2002-05-16 Raisch Kevin Paul Human anti-epidermal growth factor receptor single-chain antibodies
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2004081026A2 (en) * 2003-06-30 2004-09-23 Domantis Limited Polypeptides
WO2005012359A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Anti-vegf antibodies
WO2005044858A1 (en) * 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
[ONLINE], vol. N.NCT00077298, JPN5008020509, 10 February 2004 (2004-02-10), pages 1 - 6, ISSN: 0002135535 *
HOANG, T. ET AL., LUNG CANCER, vol. Vol.49, Suppl.2, JPN5008020510, July 2005 (2005-07-01), pages 108 - 109, ISSN: 0002135534 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527877A (ja) * 2009-05-28 2012-11-12 グラクソ グループ リミテッド 抗原結合性タンパク質
JP2012532620A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
JP2014501725A (ja) * 2010-11-24 2014-01-23 グラクソ グループ リミテッド Hgfを標的とする多特異的抗原結合タンパク質
JP2017195874A (ja) * 2016-04-26 2017-11-02 コリア プライム ファーム カンパニー リミテッドKorea Prime Pharm Co., Ltd. 血管内皮成長因子融合タンパク質

Also Published As

Publication number Publication date
CA2632417A1 (en) 2007-06-14
EA013878B1 (ru) 2010-08-30
MA30021B1 (fr) 2008-12-01
WO2007066106A1 (en) 2007-06-14
US20130041136A1 (en) 2013-02-14
KR20080077261A (ko) 2008-08-21
NO20082386L (no) 2008-08-27
US20100056439A1 (en) 2010-03-04
CR10024A (es) 2008-09-22
TW200804425A (en) 2008-01-16
EP1966242A1 (en) 2008-09-10
EA200801172A1 (ru) 2008-12-30
AU2006323412A1 (en) 2007-06-14
BRPI0619463A2 (pt) 2013-01-08

Similar Documents

Publication Publication Date Title
US7696320B2 (en) Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
JP2009518024A (ja) Egfrおよび/またはvegfに対して結合特異性を有するリガンドおよびその使用法
US20100021473A1 (en) Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
US20110159003A1 (en) Ligands That Bind Il-4 and/or Il-13
US20080241166A1 (en) Ligands that bind a receptor
WO2022179039A1 (zh) 抗人cd73抗体及其应用
JP2012509658A (ja) Il−13に結合するリガンド
CN101255196A (zh) 免疫球蛋白单个变体抗原结合区及其特异性构建体
MX2008007351A (en) Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
MX2008008854A (en) Ligands that have binding specificity for vegf and/or egfr and methods of use therefor
MX2008007369A (en) Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
MX2008009528A (en) Ligands that bind il-4 and/or il-13
KR20050024397A (ko) 리간드
HK1156053A (en) Ligand

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120525

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121009